Cisapride in neurologically impaired children with chronic constipation

Dig Dis Sci. 1996 May;41(5):870-4. doi: 10.1007/BF02091525.


The efficacy of cisapride as a treatment for chronic constipation in children with severe brain damage was studied in 20 children. Each subject was randomly assigned to double-blind treatment with either cisapride (N = 10) or placebo (N = 10) for 12 weeks. Stool habits, total gastrointestinal transit time, colonic segmental transit times, and anorectal motility were evaluated in all children before and at the end of the treatment period. Although cisapride significantly (P < 0.05) increased stool frequency from baseline to week 12 and no significant change was documented in the placebo group, the mean change in stool frequency per week from baseline to 12 week was not significantly different between the two treatment groups. The use of laxatives or suppositories was significantly (P < 0.05) decreased by cisapride, but remained unchanged in the placebo group. Furthermore, cisapride significantly (P < 0.05) reduced rectal compliance but had no effect on total gastrointestinal transit time and colonic segmental transit times. In summary, in neurologically impaired children with chronic constipation, cisapride increased bowel frequency but did not alter the delay in total and segmental gastrointestinal transit times.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Brain Damage, Chronic / complications*
  • Child
  • Child, Preschool
  • Chronic Disease
  • Cisapride
  • Constipation / drug therapy*
  • Constipation / physiopathology
  • Defecation / drug effects
  • Double-Blind Method
  • Female
  • Gastrointestinal Transit / drug effects
  • Humans
  • Infant
  • Male
  • Piperidines / therapeutic use*
  • Serotonin Receptor Agonists / therapeutic use*
  • Statistics, Nonparametric
  • Time Factors


  • Piperidines
  • Serotonin Receptor Agonists
  • Cisapride